Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249272 · ClinicalTrials.gov registry record · Phase 4
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT03249272 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 31 participants.
The verdict
NCT03249272, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve. The goal is to determine the prevalence of MVD in two common forms of non-ischemic cardiomyopathy, hypertrophic cardiomyopathy (HCM) and idiopathic dilated cardiomyopathy (IDCM). The hypothesis that an optimized technique will provide robust detection of MVD and that a multifaceted approach will provide new insights into the pathophysiology of MVD, including the influence of myocardial scarring upon the presence and severity of MVD.
Interventions
- DRUG Regadenoson
- DRUG Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03249272
The ClinicalTrials.gov registry entry for NCT03249272 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regadenoson is the first listed.
NCT03249272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03249272 about?
NCT03249272 is a clinical study titled "Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve". The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve. The goal is to determine the prevalence of MVD in two common forms of non-ischemic cardiomyopathy, hypertrophic cardiomyopathy (HCM) a...
What is the current status of trial NCT03249272?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2017-09-05. Estimated completion is 2019-03-31.
What interventions are being tested in trial NCT03249272?
The interventions under investigation include: Regadenoson (DRUG), Adenosine (DRUG).
Who is sponsoring clinical trial NCT03249272?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.